Vinorelbine treatment of advanced non-small cell lung cancer with special emphasis on elderly patients

A. Veronesi, D. Crivellari, M. D. Magri, G. Cartei, M. Mansutti, S. Foladore, S. Monfardini

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

The aim of this study was to investigate the activity and the toxicity of vinorelbine (VNB) in a population of patients with locally advanced inoperable or metastatic non-small cell lung cancer (NSCLC) including elderly patients unfit for cisplatin-based chemotherapy. VNB was administered at a dose of 25-30 mg/m2, intravenously, weekly until progression. Of the 83 patients who entered the study (median age 63 years, number of patients aged 570 years = 23, median performance status 80, stage IV in 58 patients, previous chemotherapy in 15 patients), 76 were evaluable. One complete remission and 22 partial remissions were noted (30.2% reponse rate). Toxicity was mild. Median survival was 9 months. No effect of age upon outcome was detected. Thus, single agent VNH is a reasonable option for advanced NSCLC, particularly in elderly patients.

Original languageEnglish
Pages (from-to)1809-1811
Number of pages3
JournalEuropean Journal of Cancer
Volume32
Issue number10
DOIs
Publication statusPublished - Sep 1996

Fingerprint

Non-Small Cell Lung Carcinoma
Therapeutics
Drug Therapy
vinorelbine
Cisplatin
Survival
Population

Keywords

  • Elderly patients
  • Non-small cell lung cancer
  • Vinorelbine

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Veronesi, A., Crivellari, D., Magri, M. D., Cartei, G., Mansutti, M., Foladore, S., & Monfardini, S. (1996). Vinorelbine treatment of advanced non-small cell lung cancer with special emphasis on elderly patients. European Journal of Cancer, 32(10), 1809-1811. https://doi.org/10.1016/0959-8049(96)00190-6

Vinorelbine treatment of advanced non-small cell lung cancer with special emphasis on elderly patients. / Veronesi, A.; Crivellari, D.; Magri, M. D.; Cartei, G.; Mansutti, M.; Foladore, S.; Monfardini, S.

In: European Journal of Cancer, Vol. 32, No. 10, 09.1996, p. 1809-1811.

Research output: Contribution to journalArticle

Veronesi, A, Crivellari, D, Magri, MD, Cartei, G, Mansutti, M, Foladore, S & Monfardini, S 1996, 'Vinorelbine treatment of advanced non-small cell lung cancer with special emphasis on elderly patients', European Journal of Cancer, vol. 32, no. 10, pp. 1809-1811. https://doi.org/10.1016/0959-8049(96)00190-6
Veronesi, A. ; Crivellari, D. ; Magri, M. D. ; Cartei, G. ; Mansutti, M. ; Foladore, S. ; Monfardini, S. / Vinorelbine treatment of advanced non-small cell lung cancer with special emphasis on elderly patients. In: European Journal of Cancer. 1996 ; Vol. 32, No. 10. pp. 1809-1811.
@article{f128763659a04f8aac2d0f16593d573e,
title = "Vinorelbine treatment of advanced non-small cell lung cancer with special emphasis on elderly patients",
abstract = "The aim of this study was to investigate the activity and the toxicity of vinorelbine (VNB) in a population of patients with locally advanced inoperable or metastatic non-small cell lung cancer (NSCLC) including elderly patients unfit for cisplatin-based chemotherapy. VNB was administered at a dose of 25-30 mg/m2, intravenously, weekly until progression. Of the 83 patients who entered the study (median age 63 years, number of patients aged 570 years = 23, median performance status 80, stage IV in 58 patients, previous chemotherapy in 15 patients), 76 were evaluable. One complete remission and 22 partial remissions were noted (30.2{\%} reponse rate). Toxicity was mild. Median survival was 9 months. No effect of age upon outcome was detected. Thus, single agent VNH is a reasonable option for advanced NSCLC, particularly in elderly patients.",
keywords = "Elderly patients, Non-small cell lung cancer, Vinorelbine",
author = "A. Veronesi and D. Crivellari and Magri, {M. D.} and G. Cartei and M. Mansutti and S. Foladore and S. Monfardini",
year = "1996",
month = "9",
doi = "10.1016/0959-8049(96)00190-6",
language = "English",
volume = "32",
pages = "1809--1811",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "10",

}

TY - JOUR

T1 - Vinorelbine treatment of advanced non-small cell lung cancer with special emphasis on elderly patients

AU - Veronesi, A.

AU - Crivellari, D.

AU - Magri, M. D.

AU - Cartei, G.

AU - Mansutti, M.

AU - Foladore, S.

AU - Monfardini, S.

PY - 1996/9

Y1 - 1996/9

N2 - The aim of this study was to investigate the activity and the toxicity of vinorelbine (VNB) in a population of patients with locally advanced inoperable or metastatic non-small cell lung cancer (NSCLC) including elderly patients unfit for cisplatin-based chemotherapy. VNB was administered at a dose of 25-30 mg/m2, intravenously, weekly until progression. Of the 83 patients who entered the study (median age 63 years, number of patients aged 570 years = 23, median performance status 80, stage IV in 58 patients, previous chemotherapy in 15 patients), 76 were evaluable. One complete remission and 22 partial remissions were noted (30.2% reponse rate). Toxicity was mild. Median survival was 9 months. No effect of age upon outcome was detected. Thus, single agent VNH is a reasonable option for advanced NSCLC, particularly in elderly patients.

AB - The aim of this study was to investigate the activity and the toxicity of vinorelbine (VNB) in a population of patients with locally advanced inoperable or metastatic non-small cell lung cancer (NSCLC) including elderly patients unfit for cisplatin-based chemotherapy. VNB was administered at a dose of 25-30 mg/m2, intravenously, weekly until progression. Of the 83 patients who entered the study (median age 63 years, number of patients aged 570 years = 23, median performance status 80, stage IV in 58 patients, previous chemotherapy in 15 patients), 76 were evaluable. One complete remission and 22 partial remissions were noted (30.2% reponse rate). Toxicity was mild. Median survival was 9 months. No effect of age upon outcome was detected. Thus, single agent VNH is a reasonable option for advanced NSCLC, particularly in elderly patients.

KW - Elderly patients

KW - Non-small cell lung cancer

KW - Vinorelbine

UR - http://www.scopus.com/inward/record.url?scp=0001179973&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0001179973&partnerID=8YFLogxK

U2 - 10.1016/0959-8049(96)00190-6

DO - 10.1016/0959-8049(96)00190-6

M3 - Article

C2 - 8983294

AN - SCOPUS:0001179973

VL - 32

SP - 1809

EP - 1811

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 10

ER -